Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2022-09-06 Regulatory Filings
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Abivax phase 2b study results of obefazimod (ABX464) in ulcerative colitis published in the Lancet Gastroenterology & Hepatology
Regulatory Filings Classification · 1% confidence The document is a press release dated September 6, 2022, announcing that the results of Abivax's Phase 2b study for obefazimod in ulcerative colitis have been published in 'The Lancet Gastroenterology & Hepatology'. It details the study findings, quotes investigators, and mentions the progression to Phase 3 trials. This type of announcement, which disseminates key scientific or operational news via a news service (DGAP/EQS Group AG), is typically classified as a general corporate news release or regulatory filing that doesn't fit a more specific financial report category. Since it is an announcement about scientific data publication rather than a formal financial report (like 10-K, IR, or ER), and it is not a proxy statement (DEF 14A) or a management discussion (MDA), the most appropriate general category is Regulatory Filings (RNS), which serves as a broad category for corporate news releases not covered elsewhere, especially when disseminated through official channels like DGAP.
2022-09-06 English
Abivax annonce la mise à disposition d’un prospectus dans le cadre de son augmentation de capital
Capital/Financing Update Classification · 1% confidence The document is a press release titled "ABIVAX ANNONCE LA MISE A DISPOSITION D'UN PROSPECTUS DANS LE CADRE DE SON AUGMENTATION DE CAPITAL" (ABIVAX ANNOUNCES THE AVAILABILITY OF A PROSPECTUS IN CONNECTION WITH ITS CAPITAL INCREASE). It explicitly states that an amendment to the Universal Registration Document and a prospectus approved by the AMF are being made available in connection with a capital increase. Since the document's primary function is to announce the publication/availability of other official documents (Prospectus, URD amendment) related to a financing event (capital increase), it fits the definition of a Report Publication Announcement (RPA). The document length (4075 chars) is short, supporting the 'announcement' classification over the classification of the underlying report itself. The core event is capital raising (CAP), but the document type is the announcement of the related regulatory filing/prospectus availability.
2022-09-02 French
Abivax publishes a prospectus in the context of its capital increase
Capital/Financing Update Classification · 1% confidence The document is a news release dated September 2, 2022, announcing that Abivax is publishing a prospectus in the context of a capital increase (fundraising). The text explicitly mentions the availability of a listing prospectus approved by the AMF (French regulator) and details its components (Universal Registration Document, securities note). This directly relates to the company raising capital or changing its capital structure. The definition for Capital/Financing Update (CAP) covers 'Updates on company fundraising, financing activities, or capital structure changes.' Although a prospectus is being published, the core event being announced is the capital increase, making CAP the most appropriate classification over RPA, as the focus is the financing event itself, not just the announcement of a report.
2022-09-02 English
ABIVAX: ABIVAX ANNONCE LE SUCCES D’UN FINANCEMENT CROSS-OVER SURSOUSCRIT DE 49,2 MILLIONS D’EUROS, PAR DES INVESTISSEURS AMERICAINS ET EUROPEENS DE PREMIER PLAN
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a successful financing round ('financement cross-over sursouscrit de 49,2 millions d'euros'). It details the structure of the financing, which consists of a reserved capital increase ('augmentation de capital réservée') and the issuance of royalty certificates ('émission de certificats de royalties'). The primary purpose of the funds is to finance clinical trials. This clearly falls under the category of updates on company fundraising, financing activities, or capital structure changes. Therefore, the appropriate code is 'CAP' (Capital/Financing Update). The document is a formal announcement, not a regulatory report itself, but its content is specifically about capital raising.
2022-09-02 French
Abivax annonce le succès d’un financement cross-over sursouscrit de 49,2 millions d’euros, par des investisseurs americains et europeens de premier plan
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a significant financial transaction: a 'cross-over financing' of 49.2 million Euros through a reserved capital increase and the issuance of royalty certificates. The text details the purpose of the funds (financing Phase 3 clinical studies), the investors involved, the structure of the capital raise (issuance of new shares and royalty certificates), and the impact on existing shareholding percentages. This content directly relates to fundraising, capital structure changes, and financing activities. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not an Earnings Release (ER) as it focuses on financing, not operational results, nor is it a full Annual Report (10-K) or Interim Report (IR).
2022-09-02 French
ABIVAX: Abivax announces successful oversubscribed EUR 49.2M cross-over financing with top-tier US and European Biotech investors
Capital/Financing Update Classification · 1% confidence The document is an official announcement titled "ABIVAX: Abivax announces successful oversubscribed EUR 49.2M cross-over financing with top-tier US and European Biotech investors." It details the completion of a reserved equity capital increase and the issuance of royalty certificates, which are specific mechanisms for raising capital and financing operations (advancing clinical studies). This directly relates to the company's fundraising and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document is a formal press release/news detail, not a regulatory filing like 10-K or a report itself, but the content is specifically about financing.
2022-09-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.